HEMOGLOBINOPATHY TREATMENT DRUGS MARKET ANALYSIS
Global Hemoglobinopathy Treatment Drugs Market- Regional Analysis
Among region, North America is estimated to hold a dominant position in the global hemoglobinopathy treatment drugs market over the forecast period, owing to increasing partnerships. For instance, on November 11, 2021, Emmaus Life Sciences, Inc., a U.S.-based commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced a partnership with UpScript IP Holdings, LLC., a U.S.-based direct to consumer pharmaceuticals provider to offer telehealth solutions to sickle cell disease patients, expanding access to Endari, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :